KBC Group’s United Therapeutics UTHR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $5.26M | Sell |
8,878
-14,492
| -62% | -$7.22M | 0.01% | 471 |
|
|
2025
Q4 | $11.4M | Buy |
23,370
+7,045
| +43% | +$3.28M | 0.03% | 338 |
|
|
2025
Q3 | $6.84M | Sell |
16,325
-26,241
| -62% | -$8.83M | 0.02% | 402 |
|
|
2025
Q2 | $12.2M | Sell |
42,566
-66,520
| -61% | -$19.9M | 0.03% | 328 |
|
|
2025
Q1 | $33.6M | Sell |
109,086
-13,969
| -11% | -$4.79M | 0.1% | 200 |
|
|
2024
Q4 | $43.4M | Buy |
123,055
+7,169
| +6% | +$2.64M | 0.12% | 169 |
|
|
2024
Q3 | $41.5M | Sell |
115,886
-42,455
| -27% | -$14.3M | 0.13% | 162 |
|
|
2024
Q2 | $50.4M | Buy |
158,341
+154,575
| +4,104% | +$40.9M | 0.15% | 127 |
|
|
2024
Q1 | $866K | Hold |
3,766
| – | – | ﹤0.01% | 683 |
|
|
2023
Q4 | $828K | Buy |
3,766
+1,601
| +74% | +$369K | ﹤0.01% | 705 |
|
|
2023
Q3 | $489K | Buy |
2,165
+1,345
| +164% | +$310K | ﹤0.01% | 740 |
|
|
2023
Q2 | $181K | Buy |
820
+48
| +6% | +$10.6K | ﹤0.01% | 977 |
|
|
2023
Q1 | $173K | Buy |
+772
| New | +$190K | ﹤0.01% | 1023 |
|
|
2022
Q4 | – | Sell |
-2,188
| Closed | -$458K | – | 1560 |
|
|
2022
Q3 | $458K | Buy |
2,188
+423
| +24% | +$94.6K | ﹤0.01% | 775 |
|
|
2022
Q2 | $416K | Buy |
1,765
+934
| +112% | +$190K | ﹤0.01% | 798 |
|
|
2022
Q1 | $149K | Sell |
831
-3,158
| -79% | -$602K | ﹤0.01% | 1104 |
|
|
2021
Q4 | $862K | Buy |
3,989
+1,448
| +57% | +$284K | ﹤0.01% | 750 |
|
|
2021
Q3 | $469K | Sell |
2,541
-4,015
| -61% | -$791K | ﹤0.01% | 880 |
|
|
2021
Q2 | $1.18M | Buy |
+6,556
| New | +$1.25M | ﹤0.01% | 848 |
|
|
2021
Q1 | – | Sell |
-30,802
| Closed | -$25.7M | – | 1317 |
|
|
2020
Q4 | $25.7M | Buy |
30,802
+19,816
| +180% | +$2.6M | 0.01% | 602 |
|
|
2020
Q3 | $1.11M | Buy |
+10,986
| New | +$1.21M | ﹤0.01% | 796 |
|
|
2020
Q1 | – | Sell |
-6,926
| Closed | -$610K | – | 1447 |
|
|
2019
Q4 | $610K | Sell |
6,926
-2,678
| -28% | -$236K | ﹤0.01% | 1052 |
|
|
2019
Q3 | $766K | Hold |
9,604
| – | – | 0.01% | 959 |
|
|
2019
Q2 | $750K | Hold |
9,604
| – | – | 0.01% | 943 |
|
|
2019
Q1 | $1.13M | Sell |
9,604
-601
| -6% | -$70K | 0.01% | 824 |
|
|
2018
Q4 | $1.11M | Sell |
10,205
-4,723
| -32% | -$548K | 0.01% | 714 |
|
|
2018
Q3 | $1.91M | Hold |
14,928
| – | – | 0.01% | 698 |
|
|
2018
Q2 | $1.69M | Sell |
14,928
-262
| -2% | -$28.8K | 0.01% | 650 |
|
|
2018
Q1 | $1.71M | Buy |
15,190
+3,660
| +32% | +$465K | 0.02% | 614 |
|
|
2017
Q4 | $1.71M | Sell |
11,530
-11,444
| -50% | -$1.45M | 0.01% | 629 |
|
|
2017
Q3 | $2.69M | Buy |
22,974
+783
| +4% | +$100K | 0.02% | 530 |
|
|
2017
Q2 | $2.88M | Buy |
22,191
+1,440
| +7% | +$180K | 0.03% | 498 |
|
|
2017
Q1 | $2.81M | Buy |
20,751
+545
| +3% | +$82.6K | 0.03% | 555 |
|
|
2016
Q4 | $2.9M | Buy |
20,206
+727
| +4% | +$92.8K | 0.03% | 537 |
|
|
2016
Q3 | $2.3M | Buy |
19,479
+304
| +2% | +$36.5K | 0.03% | 540 |
|
|
2016
Q2 | $2.03M | Sell |
19,175
-4,447
| -19% | -$496K | 0.03% | 528 |
|
|
2016
Q1 | $2.63M | Sell |
23,622
-2,532
| -10% | -$320K | 0.04% | 430 |
|
|
2015
Q4 | $4.1M | Sell |
26,154
-9,431
| -27% | -$1.37M | 0.08% | 307 |
|
|
2015
Q3 | $4.67M | Sell |
35,585
-6,565
| -16% | -$1.05M | 0.09% | 259 |
|
|
2015
Q2 | $7.33M | Buy |
42,150
+40,297
| +2,175% | +$7.25M | 0.09% | 263 |
|
|
2015
Q1 | $320K | Sell |
1,853
-71,324
| -97% | -$10.9M | ﹤0.01% | 1011 |
|
|
2014
Q4 | $9.48M | Buy |
73,177
+17,260
| +31% | +$2.22M | 0.11% | 218 |
|
|
2014
Q3 | $7.19M | Sell |
55,917
-37,025
| -40% | -$3.82M | 0.25% | 114 |
|
|
2014
Q2 | $8.22M | Buy |
92,942
+51,439
| +124% | +$4.95M | 0.09% | 267 |
|
|
2014
Q1 | $3.9M | Sell |
41,503
-2,004
| -5% | -$205K | 0.06% | 343 |
|
|
2013
Q4 | $4.92M | Sell |
43,507
-775
| -2% | -$69.9K | 0.07% | 317 |
|
|
2013
Q3 | $3.49M | Hold |
44,282
| – | – | 0.06% | 382 |
|
|
2013
Q2 | $2.92M | Buy |
+44,282
| New | +$2.85M | 0.05% | 403 |
|
Other funds holding UTHR
ACA
VPM
VCM
KBC Group's UTHR Position: Q1 2026 in Review
KBC Group reduced its United Therapeutics (UTHR) stake by 62% in Q1 2026, selling an estimated $7.22M and leaving 8,878 shares worth $5.26M. The position accounts for 0.01% of the portfolio, ranked #471.
KBC Group first reported a position in UTHR in Q2 2013 and has held it in 48 quarters since. The position peaked at $50.4M in Q2 2024. 851 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.
- KBC Group held 8,878 shares of United Therapeutics worth $5.26M as of Q1 2026.
- KBC Group sold 14,492 United Therapeutics shares in Q1 2026, an estimated $7.22M.
- United Therapeutics made up 0.01% of KBC Group's portfolio in Q1 2026, its #471 holding.
- KBC Group first reported a position in United Therapeutics in Q2 2013 and has held it in 48 quarters since.
- KBC Group's United Therapeutics position peaked at $50.4M in Q2 2024.
- 851 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.
Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.